Sample Size estimation for Replicate Cross over studies FDA or EMA criteria [Power / Sample Size]

posted by Lara – Mexico, 2016-02-10 01:46 (3781 d 01:09 ago) – Posting: # 15966
Views: 29,323

Hi,

I have review the paper:

Someswara Roa. K et al. "Sample Size Estimation for Highly variable drugs using reference scaled average bioequivalence criteria". International Journal of Recent Scientific Research Vol. 6 Issue 7, pp.5040-5045, July, 2015.

They are determined the optimal sample size for reference scaled average bioequivalence under criteria of FDA and EMA. The paper has several tables with the sample size according with FDA and EMA criteria for the designs partial replicate 2x2x3 and full replicate 2x2x4 and use the BE limit. However, they are using the estimation of the sample size for a simple crossover. I am not sure that this is correct starting with df=2*n-2 and I do not know when they are using the characteristics of the designs. Can somebody help me with that?

Thanks

Lara


Edit: Category changed. [Helmut]

Complete thread:

UA Flag
Activity
 Admin contact
23,654 posts in 4,992 threads, 1,571 registered users;
164 visitors (0 registered, 164 guests [including 17 identified bots]).
Forum time: 03:56 CEST (Europe/Vienna)

“Data! Data! Data!” he cried impatiently.
“I can’t make bricks without clay!”    Arthur Conan Doyle

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5